Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 19756605)

1.

Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys.

Kapetanovic IM, Muzzio M, Hu SC, Crowell JA, Rajewski RA, Haslam JL, Jong L, McCormick DL.

Cancer Chemother Pharmacol. 2010 May;65(6):1109-16. doi: 10.1007/s00280-009-1116-4. Epub 2009 Sep 16.

PMID:
19756605
2.

Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent.

Green CE, Swezey R, Bakke J, Shinn W, Furimsky A, Bejugam N, Shankar GN, Jong L, Kapetanovic IM.

Cancer Chemother Pharmacol. 2011 May;67(5):995-1006. doi: 10.1007/s00280-010-1395-9. Epub 2010 Jul 10.

3.

Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.

Supko JG, Garcia-Carbonero R, Puchalski TA, Malspeis L.

Cancer Chemother Pharmacol. 2001 Sep;48(3):202-8.

PMID:
11592341
4.

Enhanced oral bioavailability of the hydrophobic chemopreventive agent (SR13668) in beagle dogs.

Banerjee AA, Shen H, Hautman M, Anwer J, Hong S, Kapetanovic IM, Liu Y, Lyubimov AV.

Curr Pharm Biotechnol. 2013;14(4):464-9.

PMID:
23590143
5.
6.

High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.

Zhang Y, Hua Y, Benbrook DM, Covey JM, Dai G, Liu Z, Chan KK.

Cancer Chemother Pharmacol. 2006 Nov;58(5):561-9. Epub 2006 Mar 14.

PMID:
16534614
7.

Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.

Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH.

Cancer Chemother Pharmacol. 2005 Aug;56(2):145-53. Epub 2005 Apr 14.

PMID:
15830240
8.

Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications.

Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D.

J Pineal Res. 1997 Jan;22(1):45-51.

PMID:
9062870
10.

Enhanced oral bioavailability of a cancer preventive agent (SR13668) by employing polymeric nanoparticles with high drug loading.

Shen H, Banerjee AA, Mlynarska P, Hautman M, Hong S, Kapetanovic IM, Lyubimov AV, Liu Y.

J Pharm Sci. 2012 Oct;101(10):3877-85. doi: 10.1002/jps.23269. Epub 2012 Jul 20.

PMID:
22821759
11.

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.

Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.

12.

Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.

Adams WJ, McGovren JP, Dalm EA, Brewer JE, Hosley JD.

Cancer Res. 1989 Nov 15;49(22):6328-36.

13.

Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.

Chun AW, Freshwater RE, Taft DR, Gillum AM, Maniar M.

Biopharm Drug Dispos. 2011 Mar;32(2):99-111. doi: 10.1002/bdd.741. Epub 2011 Jan 14.

PMID:
21341279
14.
15.

Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.

Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE, Kitada S, Pellecchia M, Reed JC.

Cancer Chemother Pharmacol. 2008 Jan;61(1):63-73. Epub 2007 Mar 14.

PMID:
17356822
16.

Analytical determination and pharmacokinetics of robenacoxib in the dog.

Jung M, Lees P, Seewald W, King JN.

J Vet Pharmacol Ther. 2009 Feb;32(1):41-8. doi: 10.1111/j.1365-2885.2008.01035.x.

PMID:
19161454
17.
18.

Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.

Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, Krogstad DJ, De D, Mirsalis JC, Green CE.

Int J Toxicol. 2004 May-Jun;23(3):179-89.

PMID:
15204721
19.

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.

Cancer Chemother Pharmacol. 2009 Dec;65(1):55-66. doi: 10.1007/s00280-009-1002-0. Epub 2009 Apr 26.

PMID:
19396600
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk